Pieter E Postmus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6115760/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. Journal of Thoracic Oncology, 2007, 2, 706-714.	1.1	3,185
2	Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer. New England Journal of Medicine, 2007, 357, 664-672.	27.0	990
3	The IASLC Lung Cancer Staging Project: Proposals for Revision of the M Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 686-693.	1.1	895
4	Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet, The, 2002, 359, 1388-1392.	13.7	823
5	Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. European Heart Journal, 2007, 28, 1250-1257.	2.2	666
6	The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 1067-1077.	1.1	503
7	Stroke volume response during exercise measured by acetylene uptake and MRI. Physiological Measurement, 2007, 28, 1-11.	2.1	470
8	The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 1049-1059.	1.1	435
9	Noninvasively Assessed Pulmonary Artery Stiffness Predicts Mortality in Pulmonary Arterial Hypertension. Chest, 2007, 132, 1906-1912.	0.8	352
10	Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs. Cancer Cell, 2012, 21, 82-91.	16.8	307
11	Impaired left ventricular filling due to right-to-left ventricular interaction in patients with pulmonary arterial hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H1528-H1533.	3.2	259
12	Prognostic Relevance of Response Evaluation Using [¹⁸ F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 8362-8370.	1.6	243
13	Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension. European Heart Journal, 2008, 29, 1688-1695.	2.2	240
14	Prophylactic Cranial Irradiation in Extensive Disease Small-Cell Lung Cancer: Short-Term Health-Related Quality of Life and Patient Reported Symptoms—Results of an International Phase III Randomized Controlled Trial by the EORTC Radiation Oncology and Lung Cancer Groups. Journal of Clinical Oncology, 2009, 27, 78-84.	1.6	240
15	Treatment of Brain Metastases of Small-Cell Lung Cancer: Comparing Teniposide and Teniposide With Whole-Brain Radiotherapy—A Phase III Study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. Journal of Clinical Oncology, 2000, 18, 3400-3408.	1.6	223
16	Right coronary artery flow impairment in patients with pulmonary hypertension. European Heart Journal, 2007, 29, 120-127.	2.2	207
17	Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report. Journal of Thoracic Oncology, 2019, 14, 2109-2119.	1.1	189
18	Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung Cancer, 2014, 85, 19-24.	2.0	185

2

#	Article	IF	CITATIONS
19	Bisoprolol Delays Progression Towards Right Heart Failure in Experimental Pulmonary Hypertension. Circulation: Heart Failure, 2012, 5, 97-105.	3.9	184
20	Interventricular Septal Configuration at MR Imaging and Pulmonary Arterial Pressure in Pulmonary Hypertension. Radiology, 2005, 234, 710-717.	7.3	180
21	Impaired Left Ventricular Filling Due to Right Ventricular Pressure Overload in Primary Pulmonary Hypertension. Chest, 2001, 119, 1761-1765.	0.8	166
22	Outcome of Bronchial Carcinoma In Situ. Chest, 2000, 117, 1572-1576.	0.8	151
23	Phase I Study of Aerosolized SLIT Cisplatin in the Treatment of Patients with Carcinoma of the Lung. Clinical Cancer Research, 2007, 13, 2414-2421.	7.0	150
24	Traditional Versus Up-Front [¹⁸ F] Fluorodeoxyglucose–Positron Emission Tomography Staging of Non–Small-Cell Lung Cancer: A Dutch Cooperative Randomized Study. Journal of Clinical Oncology, 2006, 24, 1800-1806.	1.6	145
25	Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. European Journal of Cancer & Clinical Oncology, 1987, 23, 1409-1411.	0.7	142
26	Gemcitabine and Paclitaxel: Pharmacokinetic and Pharmacodynamic Interactions in Patients With Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 1999, 17, 2190-2190.	1.6	141
27	Early Changes of Cardiac Structure and Function in COPD Patients With Mild Hypoxemia. Chest, 2005, 127, 1898-1903.	0.8	138
28	Right Ventricular Diastolic Dysfunction and the Acute Effects of Sildenafil in Pulmonary Hypertension Patients. Chest, 2007, 132, 11-17.	0.8	138
29	The Stage Classification of Lung Cancer. Chest, 2013, 143, e191S-e210S.	0.8	135
30	The performance of 18F-fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodules. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1231-6.	6.4	129
31	Exercise Testing to Estimate Survival in Pulmonary Hypertension. Medicine and Science in Sports and Exercise, 2008, 40, 1725-1732.	0.4	129
32	Impaired Stroke Volume Response to Exercise in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2006, 47, 1732-1733.	2.8	126
33	Ventilatory and Cardiocirculatory Exercise Profiles in COPD. Chest, 2012, 142, 1166-1174.	0.8	122
34	Progressive Changes in Right Ventricular Geometric Shortening and Long-term Survival in Pulmonary Arterial Hypertension. Chest, 2012, 141, 935-943.	0.8	121
35	Right Ventricular Oscillatory Power Is a Constant Fraction of Total Power Irrespective of Pulmonary Artery Pressure. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1315-1320.	5.6	120
36	Development of [11C]erlotinib Positron Emission Tomography for <i>In Vivo</i> Evaluation of ECF Receptor Mutational Status. Clinical Cancer Research, 2013, 19, 183-193.	7.0	117

#	Article	IF	CITATIONS
37	Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1444-1449.	6.4	114
38	A comparison of noninvasive MRIâ€based methods of estimating pulmonary artery pressure in pulmonary hypertension. Journal of Magnetic Resonance Imaging, 2005, 22, 67-72.	3.4	110
39	Autofluorescence Bronchoscopy Improves Staging of Radiographically Occult Lung Cancer and Has an Impact on Therapeutic Strategy. Chest, 2001, 120, 1327-1332.	0.8	107
40	The IASLC Lung Cancer Staging Project: Data Elements for the Prospective Project. Journal of Thoracic Oncology, 2009, 4, 679-683.	1.1	107
41	Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non–Cross-Resistant Schedule. Journal of Clinical Oncology, 1999, 17, 927-927.	1.6	104
42	Progressive Dilatation of the Main Pulmonary Artery Is a Characteristic of Pulmonary Arterial Hypertension and Is Not Related to Changes in Pressure. Chest, 2010, 138, 1395-1401.	0.8	104
43	Bronchoscopic Therapy in Patients With Intraluminal Typical Bronchial Carcinoid. Chest, 1995, 107, 556-558.	0.8	103
44	Clinically Significant Change in Stroke Volume in Pulmonary Hypertension. Chest, 2011, 139, 1003-1009.	0.8	100
45	The natural course of preneoplastic lesions in bronchial epithelium. Clinical Cancer Research, 2005, 11, 537-43.	7.0	97
46	Effects of Epoprostenol on Right Ventricular Hypertrophy and Dilatation in Pulmonary Hypertension. Chest, 2004, 125, 572-579.	0.8	94
47	Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase Il study. Radiotherapy and Oncology, 1998, 46, 29-32.	0.6	91
48	Videothoracoscopic Appearance of First and Recurrent Pneumothorax. Chest, 1995, 108, 330-334.	0.8	90
49	Birt-Hogg-Dubé Syndrome: Clinical and Genetic Studies of 20 Families. Journal of Investigative Dermatology, 2008, 128, 45-49.	0.7	88
50	Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?. European Radiology, 2010, 20, 2890-2898.	4.5	87
51	Usefulness of Serial N-Terminal Pro–B-Type Natriuretic Peptide Measurements for Determining Prognosis in Patients With Pulmonary Arterial Hypertension. American Journal of Cardiology, 2011, 108, 1645-1650.	1.6	85
52	A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-NaÃ⁻ve Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research, 2010, 16, 3078-3087.	7.0	82
53	Bronchoscopic treatment of intraluminal typical carcinoid: A pilot study. Journal of Thoracic and Cardiovascular Surgery, 1998, 116, 402-406.	0.8	81
54	Initial bronchoscopic treatment for patients with intraluminal bronchial carcinoids. Journal of Thoracic and Cardiovascular Surgery, 2007, 133, 973-978.	0.8	79

#	Article	IF	CITATIONS
55	Cardiopulmonary Exercise Test Characteristics in Patients with Chronic Obstructive Pulmonary Disease and Associated Pulmonary Hypertension. Respiration, 2008, 76, 160-167.	2.6	77
56	Prevalence of Birt–Hogg–Dubé syndrome in patients with apparently primary spontaneous pneumothorax. European Respiratory Journal, 2015, 45, 1191-1194.	6.7	70
57	Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treatment Reviews, 2013, 39, 252-260.	7.7	68
58	The Effect of Right Ventricular Hypertrophy on Left Ventricular Ejection Fraction in Pulmonary Emphysema. Chest, 1997, 112, 640-645.	0.8	67
59	Early Detection of Preinvasive Lesions in High-Risk Patients. Journal of Bronchology, 1998, 5, 280-283.	0.2	61
60	Determination of stroke volume by means of electrical impedance tomography. Physiological Measurement, 2000, 21, 285-293.	2.1	60
61	Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. Pulmonary Pharmacology and Therapeutics, 2008, 21, 558-564.	2.6	60
62	Non-invasive stroke volume assessment in patients with pulmonary arterial hypertension: left-sided data mandatory. Journal of Cardiovascular Magnetic Resonance, 2008, 10, 51.	3.3	58
63	Prolonged right ventricular post-systolic isovolumic period in pulmonary arterial hypertension is not a reflection of diastolic dysfunction. Heart, 2011, 97, 473-478.	2.9	58
64	Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography. Clinical Cancer Research, 2013, 19, 4163-4173.	7.0	58
65	Determinants of pulmonary perfusion measured by electrical impedance tomography. European Journal of Applied Physiology, 2004, 92, 45-49.	2.5	56
66	Fluorescence bronchoscopy for early detection of lung cancer. Lung Cancer, 2001, 34, 157-168.	2.0	54
67	Right ventricular oxygen supply parameters are decreased in human and experimental pulmonary hypertension. Journal of Heart and Lung Transplantation, 2013, 32, 231-240.	0.6	53
68	Long-term follow-up after first-line bronchoscopic therapy in patients with bronchial carcinoids. Thorax, 2015, 70, 468-472.	5.6	53
69	Pulmonary perfusion measured by means of electrical impedance tomography. Physiological Measurement, 1998, 19, 263-273.	2.1	51
70	Response and Pattern of Failure After Photodynamic Therapy for Intraluminal Stage I Lung Cancer. Journal of Bronchology, 1994, 1, 295-298.	0.2	49
71	MRI evaluation of right ventricular pressure overload in chronic obstructive pulmonary disease. Journal of Magnetic Resonance Imaging, 1998, 8, 999-1005.	3.4	48
72	Interventricular Mechanical Asynchrony Due To Right Ventricular Pressure Overload in Pulmonary Hypertension Plays an Important Role in Impaired Left Ventricular Filling. Chest, 2005, 128, 628S-630S.	0.8	48

#	Article	IF	CITATIONS
73	Bronchoscopic treatment of patients with intraluminal microinvasive radiographically occult lung cancer not eligible for surgical resection: a follow-up study. Lung Cancer, 2003, 39, 49-53.	2.0	47
74	Assessing a System to Capture Stray Aerosol during Inhalation of Nebulized Liposomal Cisplatin. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2006, 19, 385-391.	1.2	47
75	Multiple suspicious lesions detected by autofluorescence bronchoscopy predict malignant development in the bronchial mucosa in high risk patients. Lung Cancer, 2003, 41, 295-301.	2.0	46
76	Dual digital video-autofluorescence imaging for detection of pre-neoplastic lesions. Lung Cancer, 2007, 58, 44-49.	2.0	46
77	Pulmonary Vascular Responses to Hypoxia and Hyperoxia in Healthy Volunteers and COPD Patients Measured by Electrical Impedance Tomographya. Chest, 2003, 123, 1803-1809.	0.8	45
78	Cardiac Function and Position More Than 5 Years After Pneumonectomy. Annals of Thoracic Surgery, 2007, 83, 1986-1992.	1.3	45
79	Color Fluorescence Ratio for Detection of Bronchial Dysplasia and Carcinoma <i>In situ</i> . Clinical Cancer Research, 2009, 15, 4700-4705.	7.0	45
80	High-Resolution CT in Patients With Intraluminal Typical Bronchial Carcinoid Tumors Treated With Bronchoscopic Therapy. Chest, 2000, 117, 125-128.	0.8	44
81	Quantitative Parametric Perfusion Images Using ¹⁵ O-Labeled Water and a Clinical PET/CT Scanner: Test–Retest Variability in Lung Cancer. Journal of Nuclear Medicine, 2010, 51, 1684-1690.	5.0	42
82	Side-Effects of Long-Term Administration of Erlotinib in Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1477-1480.	1.1	40
83	Results of Two Years Expenience with Fluorescence Bronchoscopy in Detection of Preinvasive Bronchial Neoplasia. Diagnostic and Therapeutic Endoscopy, 1999, 5, 77-84.	1.5	39
84	Surgical mediastinal staging in daily practice. Lung Cancer, 2005, 47, 243-251.	2.0	39
85	Predictors of mortality in inoperable chronic thromboembolic pulmonary hypertension. Respiratory Medicine, 2009, 103, 1013-1019.	2.9	39
86	DNA Copy Number Alterations in Endobronchial Squamous Metaplastic Lesions Predict Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 948-956.	5.6	38
87	Sorafenib in Patients with Advanced Non-small Cell Lung Cancer that Harbor K-Ras Mutations: A Brief Report. Journal of Thoracic Oncology, 2010, 5, 719-720.	1.1	37
88	Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H200-H207.	3.2	36
89	Close Surveillance with Long-Term Follow-up of Subjects with Preinvasive Endobronchial Lesions. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1483-1489.	5.6	35
90	Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands. Lung Cancer, 2009, 64, 110-116.	2.0	34

#	Article	IF	CITATIONS
91	Observer Variability in Histopathologic Reporting of Bronchial Biopsy Specimens. Journal of Bronchology, 2000, 7, 210-214.	0.2	32
92	EGFR mutation analysis in sputum of lung cancer patients: A multitechnique study. Lung Cancer, 2013, 82, 38-43.	2.0	32
93	What is early lung cancer?. Lung Cancer, 2004, 45, 267-277.	2.0	31
94	Why Do Patients and Caregivers Seek Answers From the Internet and Online Lung Specialists? A Qualitative Study. Journal of Medical Internet Research, 2014, 16, e37.	4.3	31
95	Actual and Predicted Postoperative Changes in Lung Function After Pneumonectomy. Chest, 2004, 125, 1735-1741.	0.8	30
96	Retrospective evaluation of thromboembolic events in patients with non-small cell lung cancer treated with platinum-based chemotherapy. Lung Cancer, 2014, 86, 73-77.	2.0	27
97	Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report. Journal of Thoracic Oncology, 2010, 5, 554-557.	1.1	26
98	Negative NKX2-1 (TTF-1) as Temporary Surrogate Marker for Treatment Selection During EGFR-Mutation Analysis in Patients with Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1522-1527.	1.1	26
99	Tumor Cavitation in Patients With Stage III Non–Small-Cell Lung Cancer Undergoing Concurrent Chemoradiotherapy: Incidence and Outcomes. Journal of Thoracic Oncology, 2012, 7, 1271-1275.	1.1	26
100	Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: A phase II study of the EORTC lung cancer cooperative group. European Journal of Cancer, 1993, 29, 204-207.	2.8	24
101	The Curative Potential of Intraluminal Bronchoscopic Treatment for Early-Stage Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2001, 2, 264-270.	2.6	24
102	Cost-Effectiveness of Early Intervention: Comparison between Intraluminal Bronchoscopic Treatment and Surgical Resection for T ₁ N₀ Lung Cancer Patients. Respiration, 2004, 71, 391-396.	2.6	24
103	Lung Density Measurements in Spontaneous Pneumothorax Demonstrate Airtrapping. Chest, 2004, 125, 2083-2090.	0.8	24
104	Detection and Staging of Preinvasive Lesions and Occult Lung Cancer in the Central Airways with 18F-Fluorodeoxyglucose Positron Emission Tomography: A Pilot Study. Clinical Cancer Research, 2005, 11, 6186-6189.	7.0	24
105	Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. Future Oncology, 2018, 14, 2415-2431.	2.4	24
106	Curative Endobronchial Therapy in Early-Stage Non-Small Cell Lung Cancer. Journal of Bronchology, 1999, 6, 198-206.	0.2	22
107	CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone. Lung Cancer, 2008, 60, 57-61.	2.0	22
108	Dramatic Response to Low-Dose Erlotinib of Epidermal Growth Factor Receptor Mutation-Positive Recurrent Non-small Cell Lung Cancer After Severe Cutaneous Toxicity. Journal of Thoracic Oncology, 2009, 4, 1585-1586.	1.1	22

#	Article	IF	CITATIONS
109	Elevated hTERT mRNA levels: A potential determinant of bronchial squamous cell carcinoma (<i>in) Tj ETQq1 1</i>	0.784314	rgBT_/Overloci
110	Development and validation of a supervised deep learning algorithm for automated wholeâ€slide programmed deathâ€ligand 1 tumour proportion score assessment in nonâ€small cell lung cancer. Histopathology, 2022, 80, 635-647.	2.9	21
111	Prognostic Factors in Patients With Spontaneous Pneumothorax Treated With Video-Assisted Thoracoscopy. Diagnostic and Therapeutic Endoscopy, 1995, 2, 1-5.	1.5	20
112	The Natural History of Carcinoma In Situ Involving Bronchial Resection Margins. Chest, 2005, 128, 1736-1741.	0.8	20
113	Effects on Smoking Cessation: Naltrexone Combined with a Cognitive Behavioral Treatment Based on the Community Reinforcement Approach. Substance Use and Misuse, 2006, 41, 45-60.	1.4	20
114	Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancer. Journal of Clinical Pathology, 2012, 65, 541-545.	2.0	20
115	The Influence of Fluticasone Inhalation on Markers of Carcinogenesis in Bronchial Epithelium. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 1061-1065.	5.6	19
116	A de novo FLCN mutation in a patient with spontaneous pneumothorax and renal cancer; a clinical and molecular evaluation. Familial Cancer, 2013, 12, 373-379.	1.9	19
117	Assessment of the Pulmonary Volume Pulse in Idiopathic Pulmonary Arterial Hypertension by Means of Electrical Impedance Tomography. Respiration, 2006, 73, 597-602.	2.6	18
118	Addition of Prostanoids in Pulmonary Hypertension Deteriorating on Oral Therapy. Journal of Heart and Lung Transplantation, 2009, 28, 280-284.	0.6	18
119	Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 547-556.	2.8	18
120	A Web Site on Lung Cancer: Who Are the Users and What Are They Looking For?. Journal of Thoracic Oncology, 2007, 2, 813-818.	1.1	17
121	Time for reappraisal of extracranial treatment options?. Cancer, 2011, 117, 597-605.	4.1	17
122	Renal imaging in 199 Dutch patients with Birt-Hogg-Dubé syndrome: Screening compliance and outcome. PLoS ONE, 2019, 14, e0212952.	2.5	17
123	Primary lung cancer after treatment of head and neck cancer without lymph node metastasis: Is there a role for autofluorescence bronchoscopy?. Lung Cancer, 2008, 62, 309-315.	2.0	16
124	Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study. OncoTargets and Therapy, 2018, Volume 11, 4573-4582.	2.0	15
125	DNA copy number aberrations in endobronchial lesions: a validated predictor for cancer. Thorax, 2014, 69, 451-457.	5.6	14
126	Spontaneous pneumothorax as indicator for Birt-Hogg-Dubé syndrome in paediatric patients. BMC Pediatrics, 2014, 14, 171.	1.7	14

#	Article	lF	CITATIONS
127	Mediastinoscopy as a standardised procedure for mediastinal lymph node staging in non-small cell lung carcinoma. European Journal of Cardio-thoracic Surgery, 2001, 19, 377-378.	1.4	13
128	Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer. Lung Cancer, 2003, 42, 3-6.	2.0	12
129	Bronchoscopy for Lung Cancer. Chest, 2005, 128, 16-18.	0.8	12
130	Positron Emission Tomography Scans Can Detect Radiographically Occult Lung Cancer in the Central Airways. Journal of Clinical Oncology, 2001, 19, 4271-4272.	1.6	11
131	Suprabasal p53 immunostaining in premalignant endobronchial lesions in combination with histology is associated with bronchial cancer. Lung Cancer, 2003, 40, 165-172.	2.0	11
132	Smoking behavior does not influence the natural course of pre-invasive lesions in bronchial mucosa. Lung Cancer, 2004, 45, 153-154.	2.0	11
133	Second-line for small cell lung cancer: how-to-do-it?. Lung Cancer, 2005, 48, 263-265.	2.0	10
134	Pemetrexed as a single agent in the therapy of advanced lung cancer. Seminars in Oncology, 2002, 29, 17-22.	2.2	10
135	Activity of pemetrexed (alimta), a new antifolate, against non-small cell lung cancer. Lung Cancer, 2002, 38, 3-7.	2.0	9
136	Combined Use of Autofluorescence Bronchoscopy and Argon Plasma Coagulation Enables Less Extensive Resection of Radiographically Occult Lung Cancer. Respiration, 2004, 71, 410-411.	2.6	9
137	Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era. Journal of Heart and Lung Transplantation, 2010, 29, 1150-1158.	0.6	9
138	The prognostic value of the tumor-stroma ratio in squamous cell lung cancer, a cohort study. Cancer Treatment and Research Communications, 2020, 25, 100247.	1.7	9
139	Website Visitors Asking Questions Online to Lung Cancer Specialists: What Do They Want To Know?. Interactive Journal of Medical Research, 2013, 2, e15.	1.4	9
140	Prognostic value of hTERT mRNA expression in surgical samples of lung cancer patients: the European Early Lung Cancer Project. International Journal of Oncology, 2010, 37, 455-61.	3.3	8
141	Evaluation of a treatment strategy for optimising preoperative chemoradiotherapy in stage III non-small-cell lung cancerâ~†â~†a~†. European Journal of Cardio-thoracic Surgery, 2009, 36, 1052-1057.	1.4	7
142	Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?. Lung Cancer, 2015, 89, 19-26.	2.0	7
143	A 31-Year-Old Man With Hemoptysis at High Altitude and Abnormal Hepatic Biochemistry Tests. Chest, 2007, 132, 1088-1092.	0.8	6
144	Comprehensive CADM1 promoter methylation analysis in NSCLC and normal lung specimens. Lung Cancer, 2011, 72, 316-321.	2.0	6

#	Article	IF	CITATIONS
145	Video-Assisted Thoracoscopy is Superior to Standard Computer Tomography of the Thorax for Selection of Patients With Spontaneous Pneumothorax for Bullectomy. Diagnostic and Therapeutic Endoscopy, 1995, 2, 89-92.	1.5	5
146	Pulmonary Nodules in a Patient With Seminoma Testis. Chest, 1996, 109, 265-266.	0.8	5
147	Magnetic resonance and nuclear imaging of the right ventricle in pulmonary arterial hypertension. Country Review Ukraine, 2007, 9, H29-H34.	0.8	5
148	Staging and Treatment for Small Cell Lung Cancer. , 1991, , 47-60.		5
149	High-dose cyclophosphamide and high-dose VP 16-213 for recurrent or refractory small cell lung cancer. A phase II study. European Journal of Cancer & Clinical Oncology, 1985, 21, 1467-1470.	0.7	4
150	Lung Attenuation Measurements in Healthy Young Adults. Respiration, 2003, 70, 143-148.	2.6	4
151	Screening and early diagnosis in lung cancer. Expert Review of Anticancer Therapy, 2008, 8, 1529-1531.	2.4	4
152	MA08.06 Impact of Depth of Response (DpR) on Survival in Patients with Advanced NSCLC Treated with First-Line Chemotherapy. Journal of Thoracic Oncology, 2017, 12, S387-S388.	1.1	4
153	Benefit of a Second Opinion for Lung Cancer: No Metastasis to the Kidney but a Synchronous Primary Renal Neoplasm. Case Reports in Oncology, 2014, 7, 122-125.	0.7	4
154	The Finding of Premalignant Lesions is Not Associated with Smoking Cessation in Chemoprevention Study Volunteers. Journal of Thoracic Oncology, 2010, 5, 1240-1245.	1.1	3
155	Can quantifying free-circulating DNA in plasma be used to identify subjects with high-grade pre-invasive endobronchial lesions?. Oncology Letters, 2013, 5, 1591-1594.	1.8	3
156	Benefit of a Second Opinion: Intrapulmonary Metastases or Multiple Primary Tumors?. Journal of Thoracic Oncology, 2013, 8, e54-e56.	1.1	3
157	Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis?. Familial Cancer, 2016, 15, 297-300.	1.9	3
158	Prophylactic cranial irradiation for stage IV small cell lung cancer, live longer or reduce morbidity of brain metastases?. Journal of Thoracic Disease, 2017, 9, 3572-3575.	1.4	3
159	A feasibility study of testing new drugs for small-cell lung cancer in patients with a poor performance status. Cancer Chemotherapy and Pharmacology, 1991, 27, 490-491.	2.3	2
160	An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary?. Journal of Thoracic Oncology, 2012, 7, e3-e5.	1.1	2
161	Changing health care costs for NSCLC, what does it mean?. Lung Cancer, 2018, 117, 62-63.	2.0	2
162	CA184-104: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) with paclitaxel/carboplatin (PC) versus placebo with PC in patients (pts) with stage IV/recurrent non-small cell lung cancer (NSCLC) of squamous histology Journal of Clinical Oncology, 2013, 31, TPS8117-TPS8117.	1.6	2

#	Article	IF	CITATIONS
163	Recombinant human interleukin-3 administered concomitantly with chemotherapy in patients with relapsed small cell lung cancer. Journal of Experimental Therapeutics and Oncology, 2002, 2, 47-52.	0.5	1
164	Bronchial typical carcinoid tumors: histological study of intra- versus extraluminal growth pattern. Lung Cancer, 2004, 44, 129-130.	2.0	1
165	Benefit of a Second Opinion for Lung Cancer: No Recurrent Disease, but Infection. Journal of Thoracic Oncology, 2012, 7, e6-e7.	1.1	1
166	Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy. Personalized Medicine, 2015, 12, 63-66.	1.5	1
167	Long Term Complete Remission of Intraluminal Squamous Cell Carcinoma by Bronchoscopic Electrosurgery. Diagnostic and Therapeutic Endoscopy, 1997, 4, 9-11.	1.5	0
168	Influence of Introduction of Positron Emission Tomography on Adherence to Mediastinal Staging Protocols and Performance of Mediastinoscopy. Journal of Oncology Practice, 2007, 3, 242-247.	2.5	0
169	Reflections on the 14th World Conference on Lung Cancer: A European Perspective. Oncologist, 2012, 17, 463-465.	3.7	0
170	Ventilator-Associated Pneumothorax: Drainage Is Not Always Necessary. Respiration, 2013, 85, 365-366.	2.6	0
171	Benefit of a second opinion: From metastatic disease to resectable lung cancer with sarcoid-like reaction. Respiratory Medicine Case Reports, 2014, 13, 26-27.	0.4	0
172	Facial Fibrofolliculomas as Indicator for Renal Cell Cancer. Japanese Journal of Clinical Oncology, 2014, 44, 609-610.	1.3	0
173	Brain metastases: costs for care need to be spend more effectively!. Annals of Palliative Medicine, 2019, 8, 207-209.	1.2	0
174	High expression of cell adhesion molecule 2 unfavorably impacts survival in non-small cell lung cancer patients with brain metastases. Journal of Thoracic Disease, 2021, 13, 2437-2446.	1.4	0
175	Renal cell cancer (RCC) due to Birt-Hogg-Dubé syndrome. Results of initial imaging and follow-up among 164 <i>FLCN</i> mutation carriers and outcome of 22 cases with RCC Journal of Clinical Oncology, 2015, 33, e15579-e15579.	1.6	0
176	Natural Course of Cysts in Birt-Hogg-Dubé Syndrome. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1474-1475.	5.6	0